Novartis terminates BrainTransporter collaboration with BioArctic; BioArctic keeps $30m upfront

What's the deal? Novartis has notified BioArctic that it is terminating the option, collaboration and licence agreement signed in August 2025 to explore a potential new treatment combining BioArctic's BrainTransporter technology with an undisclosed Novartis antibody, BioArctic announced on 2 November 2026.

Why it matters: BrainTransporter is BioArctic's proprietary approach to ferrying biologic drugs across the blood-brain barrier — the protective membrane that keeps most large-molecule medicines out of the brain — using the transferrin receptor as a shuttle. The collaboration, reported by FierceBiotech to be worth up to $800m including milestones, was designed to test that technology with a Novartis-owned antibody. Novartis decided to discontinue the programme for its own reasons, which BioArctic says are unrelated to the technology's performance.

BioArctic retains the full $30m upfront payment and will recognise the remaining unrecognised portion as revenue in 2026. The company says BrainTransporter remains available for other partners and notes it has signed five collaboration agreements using the technology to date. BioArctic is best known as the inventor of Leqembi (lecanemab), the first drug shown to slow the progression of early Alzheimer's disease, developed with partner Eisai.

Read more: BioArctic via PR Newswire, 2 November 2026 · FierceBiotech, 3 November 2026